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Introduction
Haemophagocytic lymphohistiocytosis (HLH) is a severe
condition in which there is extreme uncontrolled
inflammation, and may progress rapidly to multi-organ
failure and death. HLH may be genetic (primary HLH),
or secondary to infection or autoimmune/ autoinflam-
matory conditions; if the latter, it is also referred to as
macrophage activation syndrome (MAS). Distinguishing
between primary HLH and MAS is challenging but
important since the former requires different therapeutic
approaches including allogeneic haematopoietic stem
cell transplantation (HSCT) for long-term survival. HLH
screening tests are now being used in patients present-
ing with suspected MAS. In systemic Juvenile Idiopathic
Arthritis (sJIA), some patients demonstrate temporary
perforin expression abnormalities that resolve with dis-
ease control. The utility of other screening tests in a
rheumatology context is unknown.
Objectives
The purpose of this study was to describe the perfor-
mance of screening tests used in the HLH/MAS work
up of children presenting to a specialist paediatric rheu-
matology centre, and review outcomes of those with
screening abnormalities.
Methods
A database exists of patients who had screening tests for
suspected HLH/MAS. Screening tests (flow cytometry)
included: intracellular expression of perforin in CD56+
Natural Killer (NK) cells; CD107a Granule Release Assay
(GRA) in response to PHA in NK cells or anti-CD3 stimu-
lation of CD8 lymphocytes; in male patients Signal Lym-
phocyte Activating Molecule Associated Protein (SAP,
associated with XLP1) and X-linked Inhibitor of Apoptosis
Protein (XIAP, associated with XLP2) expression. All tests
requested by paediatric rheumatology over a 5 year period
(2007-2011) were included. Patient records and laboratory
parameters were retrospectively reviewed.
Results
22 patients (15 female), median age 6.5 years (range
0.6-16) underwent screening tests, with median follow-up
of 16 months (range 3-51). At presentation only 2/22
(9%) clinically met HLH criteria. Screening results were
available for 20 patients; 7 (35%) had at least one persis-
tent abnormality in any one of the tests; this group was
associated with 57% mortality or need for HSCT, com-
pared to 8% with no abnormality on any of the tests (p =
0.03). 6/20 (30%) had persistently abnormal GRA: their
final diagnoses were sJIA with MAS (n = 3); primary
HLH (n = 2); and overlap syndrome (n = 1). 1/4 boys
screened for XIAP had absent expression with subse-
quent genetic confirmation of XLP2. 18 patients had per-
forin screened, and 5 boys were screened for SAP
expression; all had normal results.
Conclusion
Primary HLH and MAS may overlap clinically and
screening in patients with suspected MAS is warranted;
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overall 14% had an eventual diagnosis of primary HLH.
Persistently abnormal GRA defines a high risk group
with poor outcome (mortality or need for HSCT) possi-
bly due to an unidentified HLH gene. The effect of
immunosuppression on the GRA was not assessed.
Further research is required in those with abnormal
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